Frederik Barkhof

157.1k citations

1.4k papers · 88.8k indexed · 26 hit papers · h-index 142

Pathology and Forensic Medicine top 0.01%
- Multiple Sclerosis Research Studies 588
Neurology top 0.01%
- Peripheral Neuropathies and Disorders 129
Neurology top 0.01%
- Peripheral Neuropathies and Disorders 129
Psychiatry and Mental health top 0.01%
- Dementia and Cognitive Impairment Research 361
Cognitive Neuroscience top 0.02%
- Functional Brain Connectivity Studies 185
Radiology, Nuclear Medicine and Imaging
- Advanced Neuroimaging Techniques and Applications 239
- Advanced MRI Techniques and Applications 134
Physiology
- Alzheimer's disease research and treatments 230
Rheumatology
- Systemic Lupus Erythematosus Research 131

Co-authors: Philip Scheltens Serge A.R.B. Rombouts Chris H. Polman Wiesje M. van der Flier Jeroen J.G. Geurts Cornelis J. Stam Massimo Filippi Hugo Vrenken
Cited by: Pathology and Forensic Medicine Neurology
Partner nations: Netherlands United Kingdom United States

In The Last Decade

Frederik Barkhof

1.4k papers receiving 87.0k citations

Hit Papers

15 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2022 Gut Microbiota Composition Is Related to AD Pathology
2021 Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
2021 Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
2019 Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines
2017 A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
2016 MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
2016 Arterial Spin Labeling Perfusion of the Brain: Emerging Clinical Applications
2012 Association between pathological and MRI findings in multiple sclerosis
2011 Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
2010 Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
2010 Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations
2007 Reduced resting-state brain activity in the “default network” in normal aging
2006 Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
2006 Consistent resting-state networks across healthy subjects
2006 Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
2005 Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study
2002 The clinico-radiological paradox in multiple sclerosis revisited
2001 Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
2001 A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
1999 Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability
1999 Cortical lesions in multiple sclerosis
1998 Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis
1997 Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis
1996 Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
1993 A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging
1992 Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.

Peers

Countries citing papers authored by Frederik Barkhof

Since Specialization

Citations

This map shows the geographic impact of Frederik Barkhof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederik Barkhof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederik Barkhof more than expected).

Fields of papers citing papers by Frederik Barkhof

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederik Barkhof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederik Barkhof. The network helps show where Frederik Barkhof may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Frederik Barkhof, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frederik Barkhof Line = papers co-authored together Frederik Barkhof links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Repeatability and reproducibility of brain age estimates in multiple sclerosis for three publicly available models Len Bos,David R. van Nederpelt,James H. Cole,Eva Strijbis,Bastiaan Moraal,Joost P.A. Kuijer,Bernard M.J. Uitdehaag,Frederik Barkhof,Alle Meije Wink,Hugo Vrenken,Bas Jasperse	2025	0
2	Enlarged cavum septum pellucidum as a neuroimaging signature of head impact exposure Suzie Kamps,Hugo L. Hempel,Suzan van Amerongen,Hannah de Bruin,Frederik H. Linden,Vikram Venkatraghavan,Wiesje M. van der Flier,Yolande A.L. Pijnenburg,Frederik Barkhof,Philip Scheltens,Rik Ossenkoppele,Everard G.B. Vijverberg	2025	1
3	Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis Sarmad Al‐Araji,Marcello Moccia,Alessia Bianchi,C.S. Yam,Weaam Hamed,Suraya Mohamud,Alan J. Thompson,Frederik Barkhof,Ahmed Toosy,Olga Ciccarelli	2025	0
4	The Centiloid scale: guidance on clinical context of use from the AMYPAD Consortium Ariane Bollack,Lyduine E. Collij,Mahnaz Shekari,Santiago Bullich,Núria Roé‐Vellvé,Norman Koglin,Andrew Stephens,Mark Battle,Christopher Buckley,Frederik Barkhof,Juan Domingo Gispert,Gill Farrar	2024	1
5	Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic Ilse Bader,Colin Groot,H. Stevie Tan,Jean-Marie A. Milongo,Jurre den Haan,Inge M.W. Verberk,Keir Yong,Julie Antonelle Orellina,Shannon R. Campbell,David Wilson,Argonde C. van Harten,Pauline H. B. Kok,Wiesje M. van der Flier,Yolande A.L. Pijnenburg,Frederik Barkhof,Elsmarieke van de Giessen,Charlotte E. Teunissen,Femke H. Bouwman,Rik Ossenkoppele	2024	4
6	Predicting Cognitive Decline in Amyloid-Positive Patients With Mild Cognitive Impairment or Mild Dementia Pieter J. van der Veere,Jeroen Hoogland,Leonie N.C. Visser,Argonde C. van Harten,Hanneke Rhodius‐Meester,Sietske A.M. Sikkes,Vikram Venkatraghavan,Frederik Barkhof,Charlotte E. Teunissen,Elsmarieke van de Giessen,(unknown),Johannes Berkhof,Wiesje M. van der Flier	2024	7
7	Assessment of Microvascular Disease in Heart and Brain by MRI: Application in Heart Failure with Preserved Ejection Fraction and Cerebral Small Vessel Disease Jonathan Bennett,Maud van Dinther,Paulien Voorter,Walter H. Backes,Josephine Barnes,Frederik Barkhof,Gabriella Captur,Alun D. Hughes,Carole H. Sudre,Thomas A. Treibel	2023	6
8	Interpretable machine learning for dementia: A systematic review Sophie Martin,Florence Townend,Frederik Barkhof,James H. Cole	2023	69
9	Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis Wallace Brownlee,Dan Altmann,Ferrán Prados,Katherine Miszkiel,Arman Eshaghi,Claudia A. M. Gandini Wheeler‐Kingshott,Frederik Barkhof,Olga Ciccarelli	2019	116
10	Three-Tesla MRI does not improve the diagnosis of multiple sclerosis Marloes Hagens,Jessica Burggraaff,Iris D. Kilsdonk,Marlieke L. de Vos,Niamh Cawley,Emilia Sbardella,Michaela Andělová,Michael A�mann,Johanna Lieb,Patrizià Pantano,Birgit I. Lissenberg‐Witte,Joep Killestein,Celia Oreja‐Guevara,Olga Ciccarelli,Claudio Gasperini,Carsten Lukas,Mike P. Wattjes,Frederik Barkhof,(unknown)	2018	31
11	Structural MRI correlates of cognitive impairment in patients with multiple sclerosis: A Multicenter Study Paolo Preziosa,Maria A. Rocca,Manfredo Atzori,Frederik Barkhof,Nicola De Stefano,Christian Enzinger,Franz Fazekas,Antonio Gallo,Hanneke E. Hulst,Laura Mancini,Xavier Montalbán,Elisabetta Pagani,Àlex Rovira,ML Stromillo,Gioacchino Tedeschi,Giacomo P. Comi,Massimo Filippi	2014	4
12	Spinal cord lesions in patients with clinically isolated syndrome Madeleine H Sombekke,Mike P. Wattjes,Lisanne J. Balk,Jessica Nielsen,Hugo Vrenken,Bernard M.J. Uitdehaag,Chris H. Polman,Frederik Barkhof	2012	105
13	Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions, and brain volume loss Alberto Ascherio,Kassandra L. Munger,Chantal Simon,Ludwig Kappos,CH Polman,HP Hartung,D. H. Miller,Xavier Montalbán,Gilles Edan,Frederik Barkhof,Richard White,Rupert Sandbrink,Christoph Pohl	2012	2
14	Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis Alexandra Seewann,Hugo Vrenken,Evert‐Jan Kooi,Paul van der Valk,Dirk L. Knol,Chris H. Polman,Petra J. W. Pouwels,Frederik Barkhof,Jeroen J.G. Geurts	2011	88
15	Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI Jeroen J.G. Geurts,Stefan D. Roosendaal,Massimiliano Calabrese,Olga Ciccarelli,Federica Agosta,Declan Chard,Achim Gass,Elena Charro Huerga,Bastiaan Moraal,Deborah Pareto,Maria A. Rocca,Mike P. Wattjes,Tarek Yousry,Bernard M.J. Uitdehaag,Frederik Barkhof	2011	237
16	Long-term effect of early treatment with interferon-beta-1b after a first clinical event suggestive of multiple sclerosis: 8-year observational extension of the phase 3 BENEFIT trial (unknown),Ludwig Kappos,Xavier Montalbán,C. Polman,Mitchel Freedman,HP Hartung,David Miller,Frederik Barkhof,Lanius,(unknown),Brigitte Stemper,Christoph Pohl,Rupert Sandbrink,Dirk Pleimes	2011	1
17	Ibudilast in relapsing-remitting multiple sclerosis Frederik Barkhof,Hanneke E. Hulst,Jelena Drulović,Bernard M.J. Uitdehaag,K. Matsuda,Ronald J. Landin	2010	109
18	MRI criteria for MS in patients with clinically isolated syndromes Xavier Montalbán,Mar Tintoré,Josephine Swanton,Frederik Barkhof,Franz Fazekas,Massimo Filippi,Jette Lautrup Frederiksen,Ludwig Kappos,Jacqueline Palace,C.H. Polman,Marco Rovaris,Nicola De Stefano,Alan J. Thompson,Tarek Yousry,Àlex Rovira,D. H. Miller	2010	179
19	Betaferon in newly emerging multiple sclerosis for initial treatment (BENEFIT): First results Ludwig Kappos,C.H. Polman,M. S. Freedman,Gilles Edan,HP Hartung,DW Miller,Xavier Montalbán,Frederik Barkhof,Lars Bauer,Peter Jakobs,P Sandbrink	2005	3
20	T1 HYPOINTENSITIES AND AXONAL LOSS Frederik Barkhof,Giorgos B. Karas,Marianne AA van Walderveen	2000	35

About Frederik Barkhof

Frederik Barkhof is a scholar working on Pathology and Forensic Medicine, Psychiatry and Mental health and Neurology, having authored 1.4k papers that have together received 88.8k indexed citations. Recurring topics across this work include Multiple Sclerosis Research Studies (588 papers), Dementia and Cognitive Impairment Research (361 papers), Advanced Neuroimaging Techniques and Applications (239 papers), Alzheimer's disease research and treatments (230 papers), Functional Brain Connectivity Studies (185 papers), Advanced MRI Techniques and Applications (134 papers), Systemic Lupus Erythematosus Research (131 papers) and Peripheral Neuropathies and Disorders (129 papers). The work is most often cited by research in Pathology and Forensic Medicine (35.5k citations), Neurology (11.5k citations) and Neurology (20.2k citations). Frederik Barkhof has collaborated with scholars based in Netherlands, United Kingdom and United States. Frequent co-authors include Philip Scheltens, Serge A.R.B. Rombouts, Chris H. Polman, Wiesje M. van der Flier, Jeroen J.G. Geurts, Cornelis J. Stam, Massimo Filippi, Hugo Vrenken, Jessica S. Damoiseaux and Ludwig Kappos.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact